Role of micafungin in the antifungal armamentarium

被引:28
作者
Ikeda, Fumiaki [1 ]
Tanaka, Shigeki [1 ]
Ohki, Hidenori [1 ]
Matsumoto, Satoru [1 ]
Maki, Katsuyuki [1 ]
Katashima, Masataka [1 ]
Barrett, David [1 ]
Aoki, Yoshiyasu [1 ]
机构
[1] Astellas Pharma Inc, Dev Div, Itabashi Ku, Tokyo 1748612, Japan
关键词
D O I
10.2174/092986707780597970
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Serious infections caused by opportunistic molds remain a major problem for public health. Immune deficiency following organ transplantation and aggressive cancer treatment has greatly increased the incidence of systemic mycoses, and invasive aspergillosis in patients with AIDS is associated with significant morbidity and mortality. Amphotericin B is the first-line therapy for systemic infection because of its broad-spectrum and fungicidal activity. However, considerable side effects limit its clinical utility. The echinocandins are large lipopeptide molecules that inhibit the synthesis of 1,3-beta-D-glucan, a key component of the fungal cell wall. Three echinocandins have reached the market, and some others are in early clinical development. Caspofungin was the first echinocandin to be licensed for clinical use in most countries. Micafungin is licensed for clinical use in Japan, China, Taiwan, Jordan, Korea, Hong-Kong and the US, and anidulafungin is currently licensed in the US. The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. Studies to date have shown that micalungin exhibits extremely potent antifungal activity against clinically important fungi, including Aspergillus and azole-resistant strains of Candida. In animal studies, micafungin is as efficacious as amphotericin B with respect to improvement of survival rate. Micafungin is also characterized by a linear pharmacokinetic profile and substantially fewer toxic effects. Micafungin is a poor substrate for the cytochrome P450 enzymes, and compared to azoles, fewer drug interactions are described. No dose adjustments of the drug are required in the presence of mycophenolate mofetil, cyclosporin, tacrolimus, prednisolone, or sirolimus. Strategies using this new echinocandin agent will benefit a large number of patients with severe immune dysfunction.
引用
收藏
页码:1263 / 1275
页数:13
相关论文
共 49 条
[1]  
AZUMA J, 2002, CHENMOTHERAPY TOKYO, V50, P148
[2]  
AZUMA J, 2002, JPN J CHEMOTHER S1, V50, P155
[3]   From natural products to clinically useful antifungals [J].
Barrett, D .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :224-233
[4]   Newer systemic antifungal agents - Pharmacokinetics, safety and efficacy [J].
Boucher, HW ;
Groll, AH ;
Chiou, CC ;
Walsh, TJ .
DRUGS, 2004, 64 (18) :1997-2020
[5]   A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients [J].
de Wet, N ;
Llanos-Cuentas, A ;
Suleiman, J ;
Baraldi, E ;
Krantz, EF ;
Della Negra, M ;
Diekmann-Berndt, H .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :842-849
[6]   A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis [J].
de Wet, NTE ;
Bester, AJ ;
Viljoen, JJ ;
Filho, F ;
Suleiman, JM ;
Ticona, E ;
Llanos, EA ;
Fisco, C ;
Lau, W ;
Buell, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :899-907
[7]   ANTIBIOTICS THAT INHIBIT FUNGAL CELL-WALL DEVELOPMENT [J].
DEBONO, M ;
GORDEE, RS .
ANNUAL REVIEW OF MICROBIOLOGY, 1994, 48 :471-497
[8]   Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].
Denning, David W. ;
Marr, Kieren A. ;
Lau, Wendi M. ;
Facklam, David P. ;
Ratanatharathorn, Voravit ;
Becker, Cornelia ;
Ullmann, Andrew J. ;
Seibel, Nita L. ;
Flynn, Patricia M. ;
van Burik, Jo-Anne H. ;
Buell, Donald N. ;
Patterson, Thomas F. .
JOURNAL OF INFECTION, 2006, 53 (05) :337-349
[9]   Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors [J].
Douglas, CM ;
DIppolito, JA ;
Shei, GJ ;
Meinz, M ;
Onishi, J ;
Marrinan, JA ;
Li, W ;
Abruzzo, GK ;
Flattery, A ;
Bartizal, K ;
Mitchell, A ;
Kurtz, MB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2471-2479
[10]   FR131535, a novel water-soluble echinocandin-like lipopeptide: Synthesis and biological properties [J].
Fujie, A ;
Iwamoto, T ;
Sato, B ;
Muramatsu, H ;
Kasahara, C ;
Furuta, T ;
Hori, Y ;
Hino, M ;
Hashimoto, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (03) :399-402